Molecular analysis of the carbapenem and metronidazole resistance mechanisms of *Bacteroides* strains reported in a Europe-wide antibiotic resistance survey

Józef Sóki*, Zsuzsa Eitel, Edit Urbán, Elisabeth Nagy, on behalf of the ESCMID Study Group on Anaerobic Infections

Institute of Clinical Microbiology, Faculty of Medicine, University of Szeged, Semmelweis 6, H-6725 Szeged, Hungary

**Article Info**

**Abstract**

Here we examine the carbapenem and metronidazole resistance mechanisms of 640 *Bacteroides* strains reported in the 2008–2009 European antibiotic susceptibility survey. Of the 22 strains with elevated imipenem minimum inhibitory concentrations (≥4 μg/mL), 10 were *cfIA*-positive and out of these 5 carried activating insertion sequence (IS) elements in the upstream regions of the *cfIA* genes. However, resistant strains with *cfIA* genes but with no activating IS elements were found (n = 2) as well as a resistant strain with no *cfIA* gene. In the former the resistance phenotypes by Etest were heterogeneous, whilst in the latter no carbapenemase production was seen; both mechanisms have been rarely observed, examined and characterised. Interestingly, few (n = 3) *nim*-positive strains were found, including one metronidazole-resistant strain harbouring *nimE* activated by IS86, and two susceptible strains harbouring chromosomally located *nim* genes.

© 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

1. Introduction

*Bacteroides* spp. represent one of the most significant groups of anaerobic bacteria. They are important constituents of the intestinal microbiota, from where they can cause severe anaerobic infections ranging from those of the soft tissue and upper respiratory tract to sepsis and various abscesses [1]. *Bacteroides* spp. can harbour the highest number of antibiotic resistance mechanisms and have the highest antibiotic resistance prevalences among all pathogenic anaerobes [2]. Because of their special and usually long culture requirements, temporary records of antibiotic resistance rates is considered a good and recommended practice worldwide. Such monitoring was performed mostly in the USA [3] and Europe [4], the latter under the organisation of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Antimicrobial Resistance in Anaerobic Bacteria (ESGARAB), whose name was changed to the ESCMID Study Group on Anaerobic Infections to cover a broader interest. The general trend is almost 100% resistance to penicillins, cephalosporins and tetracycline, a rising moderate resistance prevalence to cefoxitin, clindamycin and moxifloxacin, and very low prevalences for carbapenems, β-lactam/β-lactamase combinations, metronidazole and tigecycline [3,4]. Following antibiotic resistance monitoring for *Bacteroides* in 2000, molecular analyses were carried out to determine the metronidazole and carbapenem resistance mechanisms [5,6]. These investigations demonstrated the roles of the *nim* and *cfIA* genes and their activating insertion sequence (IS) elements in metronidazole and carbapenem resistance mechanisms, respectively.

Carbapenem-resistant *Bacteroides* isolates usually belong to the *Bacteroides fragilis* group, with the *cfIA* resistance gene being chromosomal and the majority of *cfIA*-positive strains being susceptible phenotypically because of the lack of upregulating IS elements [1]. The best-characterised metronidazole resistance mechanism among *Bacteroides* strains is due to the *nim* genes (*nimA–F*) that may occur in all *Bacteroides* species, and they are either located on well-characterised plasmids or on the chromosome. The majority of *nim*-positive *Bacteroides* isolates studied harbour a *nim* gene and a corresponding IS element pair [6]. It is of interest that the *cfIA*-positive *B. fragilis* isolates form a subgroup within this species. The *cfIA*-negative and *cfIA*-positive strains are therefore often classified as Division I and II, respectively, and can be distinguished by differences in DNA–DNA homology rates and by molecular typing methods such as randomly amplified polymorphic DNA polymerase chain reaction (RAPD-PCR), ribotyping, multilocus enzyme electrophoresis, sequence typing and
matrix-assisted laser-desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry [7–12]. The Ambler class A cephalosporinase gene, cepA, and the enterotoxin bfp genes were reported to occur exclusively in Division I strains [10].

This study investigated the prevalences of the cfiA and nim genes, the imipenem and metronidazole resistance mechanisms in the majority of *Bacteroides* strains reported in the 2008 European *Bacteroides* antibiotic resistance survey.

2. Materials and methods

2.1. Bacterial strains and cultivation

A total of 640 isolates belonging to the *Bacteroides* and *Parabacteroides* genera (486 *B. fragilis*, 54 *Bacteroides thetaiotaomicron*, 36 *Bacteroides ovatus*, 33 *Bacteroides vulgatus*, 8 *Bacteroides uniformis*, 7 *Parabacteroides distasonis*, 4 *Parabacteroides merdae*, 3 *Bacteroides eggerthii*, 3 *Bacteroides massilensis*, 3 *Bacteroides nordii*, 2 *Bacteroides caccae* and 1 *Bacteroides stercoris*) were analysed from the collection sent to the central laboratory (Institute of Clinical Microbiology, University of Szeged, Szeged, Hungary) for the 2008–2009 European *Bacteroides* antibiotic susceptibility survey (participating countries: Belgium, Croatia, Czech Republic, Finland, France, Germany, Greece, Hungary, Italy, Spain, Sweden, The Netherlands and Turkey). Isolate identification was carried out by routine clinical methods. Strains were stored at −70 °C in CryoBank vials (Mast Diagnostica, Rheinfeld, Germany) and were cultivated at 37 °C anaerobically on Columbia agar supplemented with 5% (v/v) sheep blood, 5 g/L haemin and 1 g/L vitamin K1, or in BHIS broth [brain–heart infusion broth supplemented with 0.5% (w/v) yeast extract, 5 g/L haemin and 1 g/L vitamin K1] in an anaerobic cabinet (Concept 400; Ruskin Technology Ltd., Bridgend, UK) under a gas composition of 85% N2, 10% H2 and 5% CO2 for 48 h. Antibiotic resistance results were obtained from the susceptibility measurements done previously by the agar dilution method [4] or by Etest (bioMérieux, Marcy-l’Étoile, France) as recommended by the supplier. The following control strains were used: *B. fragilis* TAL3636 (cfaA); *B. fragilis* 638R (pIP417) (nimA); *B. fragilis* BF-8 (nimB); *B. fragilis* 638R (pIP419) (nimC); *B. fragilis* 638R (pIP421) (nimD); and *B. fragilis* 388 (nimE).

2.2. Real-time PCR detection of the cfiA and nim genes

Bacterial template DNA samples for the real-time PCR analysis were prepared by incubating 100 μL of 0.5 McFarland turbidity suspensions at 100 °C for 10 min, which were stored at −30 °C until use. Real-time PCR experiments were carried out in an MXPro3000 instrument (Stratagene, Santa Clara, CA) with the following reaction setup: 1× MasterMix [Q™ (Bio-Rad Hungary, Budapest, Hungary)] with 1× EvaGreen® (Biotium Inc., Hayward, CA) for nim; or Brilliant III (Stratagene/Agilent, Santa Clara, CA) for cfiA and bfp. 0.7 μM of each primer and 2 μL of template DNA preparation in 10 μL final volumes in 96-well PCR reaction plates. The nucleotide sequences of the newly used primers and the cycling conditions chosen during this study are shown in Table 1. Positive reactions were identified by the starting amplification cycle, melting curves showing the correct melting temperatures, and in rare cases where it was required to compare the size of the products with those of the positive controls in 1.2% agarose gel electrophoresis.

### Table 2

Analysis of the imipenem resistance mechanism of strains with elevated imipenem minimum inhibitory concentrations (MICs) (>4 μg/mL).

<table>
<thead>
<tr>
<th>Strain</th>
<th>Imipenem MIC (μg/mL)</th>
<th>cfiA</th>
<th>Upstream region</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Bacteroides fragilis</em> SW42</td>
<td>4</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>B. fragilis</em> SW46</td>
<td>4</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>B. fragilis</em> SW83</td>
<td>4</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>B. fragilis</em> TR38</td>
<td>4</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>B. fragilis</em> HU25</td>
<td>4</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>B. fragilis</em> HU63</td>
<td>4</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>B. fragilis</em> eggerthii GR67</td>
<td>4</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>Bacteroides thetaiotaomicron</em> BEM28</td>
<td>4</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>Parabacteroides merdae</em> GR70</td>
<td>4</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>B. fragilis</em> DE14</td>
<td>4</td>
<td>+</td>
<td>280 bp</td>
<td>Silent with increased MIC</td>
</tr>
<tr>
<td><em>B. fragilis</em> HU51</td>
<td>4</td>
<td>+</td>
<td>280 bp</td>
<td>Silent with increased MIC</td>
</tr>
<tr>
<td><em>B. fragilis</em> IT15</td>
<td>4</td>
<td>−</td>
<td>IS4351</td>
<td>IS-activated</td>
</tr>
<tr>
<td><em>Bacteroides stercoris</em> HU59</td>
<td>8</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>B. thetaiotaomicron</em> BEA22</td>
<td>8</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
<tr>
<td><em>B. fragilis</em> HU92</td>
<td>8</td>
<td>+</td>
<td>280 bp</td>
<td>Silent with increased MIC</td>
</tr>
<tr>
<td><em>B. fragilis</em> TR27</td>
<td>16</td>
<td>+</td>
<td>IS1187</td>
<td>IS-activated</td>
</tr>
<tr>
<td><em>B. fragilis</em> TR31</td>
<td>16</td>
<td>+</td>
<td>IS1187</td>
<td>IS-activated</td>
</tr>
<tr>
<td><em>B. fragilis</em> HU61</td>
<td>32</td>
<td>+</td>
<td>280 bp</td>
<td>Heteroresistant</td>
</tr>
<tr>
<td><em>B. fragilis</em> HU63</td>
<td>&gt;32</td>
<td>+</td>
<td>IS30</td>
<td>IS-activated</td>
</tr>
<tr>
<td><em>B. fragilis</em> FR41</td>
<td>&gt;32</td>
<td>+</td>
<td>IS30</td>
<td>IS-activated</td>
</tr>
<tr>
<td><em>B. fragilis</em> FI78</td>
<td>&gt;32</td>
<td>+</td>
<td>IS6148</td>
<td>IS-activated</td>
</tr>
<tr>
<td><em>B. fragilis</em> FI37</td>
<td>&gt;32</td>
<td>−</td>
<td>−</td>
<td>Other</td>
</tr>
</tbody>
</table>

* The effects are not caused by cfiA.

* The 280-bp PCR fragment displays no insertion upstream of cfiA.
2.3. Analysis of the carbapenem and metronidazole resistance mechanisms by molecular methods

An analysis of the carbapenem and metronidazole resistance mechanisms was carried out as previously described [14,15]. Imipenemase activities were recorded in a 50 mM NaPO4 (pH 7.0) buffer using sonicated cell extracts and 0.1 mM imipenem by following absorbance changes at 299 nm. Protein concentrations were measured with a Quant-IT™ Protein Assay Kit using a Qubit® Mini Fluorometer (Life Technologies Hungary Ltd., Budapest, Hungary). Tazobactam (10 μg/mL) or 10 mM ethylene diamine tetra-acetic acid (EDTA) were used to inhibit the enzymes, and imipenemase activity was expressed as 1 nmol hydrolysed imipenem/min (1 U) standardised by the protein concentration of the sonicates. Nucleotide sequencing was performed using an automated sequencer as described previously [15]. The novel nucleotide sequence of IS8817 was deposited in the GenBank database under accession no. GQ449386.

3. Results and discussion

3.1. Resistance mechanisms of Bacteroides strains with elevated imipenem minimum inhibitory concentrations (MICs)

Of the 640 Bacteroides strains included in this study, 22 had imipenem MICs ≥ 4 μg/mL. Of the 486 B. fragilis strains examined, 43 were cfiA-positive, and from the 640 Bacteroides isolates examined 22 and 7 had imipenem MICs ≥4 μg/mL and ≥16 μg/mL, respectively. No non-fragilis Bacteroides strains were resistant to imipenem and only one cfiA-negative B. fragilis isolate was resistant. The results are summarised in Table 2. Of the 10 B. fragilis strains with elevated imipenem MICs (4–8 μg/mL), 4 (40.0%) were cfiA-positive, whilst 6 (85.7%) of the 7 imipenem-resistant (MIC ≥ 16 μg/mL) B. fragilis isolates were cfiA-positive. Among the strains with elevated MICs and with cfiA genes, one harboured an IS element upstream of cfiA (B. fragilis IT15), and among the cfiA-positive and imipenem-resistant strains four harboured IS elements upstream of the resistance gene (Table 2). The remaining two cfiA-positive isolates that were imipenem-resistant but without activating IS elements upstream of cfiA displayed a heterogeneous resistance phenotype using the imipenem Etest (see the example in Fig. 1).

This study yielded similar prevalence values for the molecular mechanisms of imipenem resistance of B. fragilis strains as those in previous studies. Among the highly imipenem-resistant strains (MIC ≥ 16 μg/mL), the cfiA genes are activated by IS elements (4 of 6 cfiA-positive), and among strains with elevated imipenem MICs (≥4 μg/mL) the cfiA genes were enriched (26.7% compared with the commonly found 2–8%). The types of cfiA-activating IS elements were IS1878 (n = 2), IS6148 (n = 1), and a novel IS element (n = IS8817; GenBank accession no. GQ449386) for B. fragilis H3 that had 77% homology compared with IS6148 (Table 2). Bacteroides fragilis IT15 harboured IS4251 upstream of the cfiA gene, but its imipenem MIC was low (4 μg/mL). This latter finding is in accordance with that of Podgajen et al. [8] who found that B. fragilis strains carrying IS4251 upstream of the cfiA genes also tended to have low imipenem MICs (16 μg/mL) compared with other IS elements (IS942 and IS1868; MICs ≥ 64 μg/mL). Previously we detected a probably low-activity Bacteroides promoter-like sequence in the upstream regions of the cfiA genes. According to this, our study and other studies detected elevated imipenemase activities in ‘silent’ cfiA-positive strains that could account for the imipenem MICs in such strains [14,16]. However, some highly imipenem-resistant strains (n = 2) were also genetically silent, their cfiA genes not being activated by IS elements (Table 2). In these cases Etest susceptibility tests detected heterogeneous resistance phenotypes (Fig. 1) where, inside of confluent inhibition zones, resistant colonies or growth appeared. This phenomenon can be explained by activation of the cfiA genes by an as yet unidentified mechanism that boosts the carbapenemase activity of the strains. We previously described such heteroresistant strains from human faeces whose imipenem MICs and imipenemase activities displayed a relation. In contrast, the cfiA genes were not activated by IS elements [16]. For Bacteroides, we detected heterogeneously cefoxitinin-resistant strains and hypothesised that the copy number of the corresponding cfiA resistance gene might be important [17].

A cfiA-negative but imipenem-resistant B. fragilis isolate was identified in this study (B. fragilis FL37; Table 2). Such strains were also found previously, but the exact carbapenem resistance mechanism for these strains has not yet been clarified [18,19]. An imipenemase assay of this strain did not reveal any activity, whilst the control B. fragilis TAL3636 strain produced 41.0 U/mg imipenemase activity that was inhibited by EDTA. The probable resistance mechanisms are penicillin-binding protein (PBP) affinity or permeability changes.

A strain-dependent role for PBPs in the case of eight B. fragilis strains with various imipenem MICs (0.12–16 μg/mL) was reported

Please cite this article in press as: Sóki J, et al. Molecular analysis of the carbapenem and metronidazole resistance mechanisms of Bacteroides strains reported in a Europe-wide antibiotic resistance survey. Int J Antimicrob Agents (2012), http://dx.doi.org/10.1016/j.ijantimicag.2012.10.001
previously [19], and mutations of an endogenous efflux system (bmeABC) also affected the carbapenem susceptibilities of the carrying strains [20].

3.2. Detection of nim genes and their relation to metronidazole resistance

Of the 640 Bacteroides strains, 21 had reduced susceptibility to metronidazole (MIC ≥ 4 μg/mL) and only 3 (B. fragilis IT724 and IT797 and B. thetaiotaomicron HU66) harboured nim genes, with the following metronidazole MICs: 0.125 μg/mL (B. fragilis IT797), 1 μg/mL (B. fragilis IT724) and 256 μg/mL (B. thetaiotaomicron HU66). An examination of the nim-mediated resistance mechanisms revealed that B. fragilis IT797 and IT724 harboured chromosomal nimA and nimC genes, respectively. By contrast, the nimE gene of B. thetaiotaomicron HU66 was located on an 8.3 kb (pBF388-like) [15] plasmid and was activated by ISBf6 (data not shown). No nim-specific plasmids were detected in the two other strains (a 5.6 kb class III plasmid and no plasmid content were characteristic for B. fragilis IT797 and IT724, respectively). Furthermore, B. fragilis IT797 harboured IS1768 and IS1770, but these elements could not be mapped to the nimA gene by PCR mapping. From these results, it appears that the situation with nim-mediated metronidazole-resistant Bacteroides strains has changed in Europe compared with the previous study where 43 Bacteroides strains with reduced metronidazole susceptibility (MICs ≥ 4 μg/mL; 3.3% and 30 (2.0%) nim-positive strains were found [6]. The current situation in Europe is reminiscent of that in the USA where nim genes and metronidazole resistances were scarce for a long time [21]. The nim-negative but metronidazole-resistant Bacteroides strains found in the current study may have other resistance mechanisms (reduced uptake, nitroreductase and pyruvate–ferredoxin oxidoreductase activities, increased lactate dehydrogenase activity, or mutations that alter the carbohydrate utilisation affecting the redox state) which shortcut the detrimental cellular effects of this drug [22–24].

In conclusion, these results confirmed the present view of carbapenem and metronidazole resistance mechanisms of Bacteroides spp but also provide new information regarding their current state and epidemiology in Europe in addition to newly described mechanisms such as non-carbapenemase-mediated imipenem resistance and chromosomal nim genes.

Funding: This study was supported by the Excellence Centre of the University of Szeged (Szeged, Hungary) (TÁMOP 421B), the Hungarian National Research Fund (OTKA 69044) and the ESCMID Study Group of Anaerobic Infections.

Competing interests: None declared.

Ethical approval: Not required.

References

women. Chimeric Bacteroides fragilis BmeABC efflux systems were found in a mutant with pre-existing antimicrobial resistance. J Antimicrob Chemother 2006;58:37–46.

Please cite this article in press as: Sóki J, et al. Molecular analysis of the carbapenem and metronidazole resistance mechanisms of Bacteroides strains reported in a Europe-wide antibiotic resistance survey. Int J Antimicrob Agents (2012),

http://dx.doi.org/10.1016/j.ijantimicag.2012.10.001